Literature DB >> 23584380

Modelling synergistic interactions between HER2, Sprouty2 and PTEN in driving prostate carcinogenesis.

Imran Ahmad1, Meiling Gao, Rachana Patel, Hing Y Leung.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23584380      PMCID： PMC3739641          DOI： 10.1038/aja.2013.40

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  23 in total

1.  HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer.

Authors:  Imran Ahmad; Rachana Patel; Lukram Babloo Singh; Colin Nixon; Morag Seywright; Robert J Barnetson; Valerie G Brunton; William J Muller; Joanne Edwards; Owen J Sansom; Hing Y Leung
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

2.  A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression.

Authors:  Pradip K Majumder; Chiara Grisanzio; Fionnuala O'Connell; Marc Barry; Joseph M Brito; Qing Xu; Isil Guney; Raanan Berger; Paula Herman; Rachel Bikoff; Giuseppe Fedele; Won-Ki Baek; Shunyou Wang; Katharine Ellwood-Yen; Hong Wu; Charles L Sawyers; Sabina Signoretti; William C Hahn; Massimo Loda; William R Sellers
Journal:  Cancer Cell       Date:  2008-08-12       Impact factor: 31.743

3.  Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation.

Authors:  X Wu; J Wu; J Huang; W C Powell; J Zhang; R J Matusik; F O Sangiorgi; R E Maxson; H M Sucov; P Roy-Burman
Journal:  Mech Dev       Date:  2001-03       Impact factor: 1.882

Review 4.  Molecular genetics of prostate cancer: new prospects for old challenges.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Genes Dev       Date:  2010-09-15       Impact factor: 11.361

Review 5.  From basic research to clinical development of MEK1/2 inhibitors for cancer therapy.

Authors:  Christophe Frémin; Sylvain Meloche
Journal:  J Hematol Oncol       Date:  2010-02-11       Impact factor: 17.388

6.  Pten is essential for embryonic development and tumour suppression.

Authors:  A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

7.  TAK1-mediated serine/threonine phosphorylation of epidermal growth factor receptor via p38/extracellular signal-regulated kinase: NF-{kappa}B-independent survival pathways in tumor necrosis factor alpha signaling.

Authors:  Miki Nishimura; Myoung-Sook Shin; Pattama Singhirunnusorn; Shunsuke Suzuki; Miho Kawanishi; Keiichi Koizumi; Ikuo Saiki; Hiroaki Sakurai
Journal:  Mol Cell Biol       Date:  2009-08-17       Impact factor: 4.272

8.  HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.

Authors:  Ingo K Mellinghoff; Igor Vivanco; Andrew Kwon; Chris Tran; John Wongvipat; Charles L Sawyers
Journal:  Cancer Cell       Date:  2004-11       Impact factor: 31.743

9.  Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy.

Authors:  Dana Faratian; Andrew H Sims; Peter Mullen; Charlene Kay; Inhwa Um; Simon P Langdon; David J Harrison
Journal:  PLoS One       Date:  2011-08-31       Impact factor: 3.240

10.  Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.

Authors:  Brett S Carver; Caren Chapinski; John Wongvipat; Haley Hieronymus; Yu Chen; Sarat Chandarlapaty; Vivek K Arora; Carl Le; Jason Koutcher; Howard Scher; Peter T Scardino; Neal Rosen; Charles L Sawyers
Journal:  Cancer Cell       Date:  2011-05-17       Impact factor: 31.743
View more
  2 in total

1.  Global advances in prostate cancer diagnosis and therapy.

Authors:  Guneet Walia; Yinghao Sun; Howard R Soule
Journal:  Asian J Androl       Date:  2013-04-22       Impact factor: 3.285

2.  Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1.

Authors:  Rachana Patel; Janis Fleming; Ernest Mui; Carolyn Loveridge; Peter Repiscak; Arnaud Blomme; Victoria Harle; Mark Salji; Imran Ahmad; Katy Teo; Freddie C Hamdy; Ann Hedley; Niels van den Broek; Gillian Mackay; Joanne Edwards; Owen J Sansom; Hing Y Leung
Journal:  EMBO Mol Med       Date:  2018-04       Impact factor: 12.137
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.